{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360004232266634752.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.jdiacomp.2016.05.018"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S1056872716301714?httpAccept=text/plain"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S1056872716301714?httpAccept=text/xml"}},{"identifier":{"@type":"PMID","@value":"27267268"}},{"identifier":{"@type":"HANDLE","@value":"10553/42450"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials"}],"description":[{"notation":[{"@value":"To evaluate the impact of β-cell function on the efficacy of lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D).In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical trials randomized to lixisenatide 20μg once daily were stratified into quartiles by baseline β-cell function, as measured by the secretory units of islet in transplantation (SUIT) index.Patients (N=437) were distributed evenly among SUIT index quartiles 1 to 4 (lowest to highest β-cell function). Clinical outcomes improved from baseline across all SUIT quartiles; mean changes at week 24 were: glycated hemoglobin (HbA1c; % [mmol/mol]), -0.99 (-10.8), -0.87 (-9.5), -0.86 (-9.4), -0.83 (-9.1); and postprandial plasma glucose (PPG; mmol/L), -7.9, -5.6, -5.5, -4.3 (overall effect P0.0001). Furthermore, postprandial glucagon was reduced in all SUIT quartiles, while insulinogenic index improved only in patients with higher baseline SUIT (overall effect P=0.0286). No severe symptomatic hypoglycemic events were reported.Lixisenatide treatment resulted in reductions in HbA1c and PPG levels across all SUIT quartiles. This suggests that non-insulin-related actions of lixisenatide contribute to improved glycemic control in T2D."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1420001326233833600","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"60378643"},{"@type":"NRID","@value":"1000060378643"},{"@type":"ORCID","@value":"0000-0002-5334-7687"},{"@type":"NRID","@value":"9000311061588"},{"@type":"NRID","@value":"9000399240954"},{"@type":"NRID","@value":"9000004037890"},{"@type":"NRID","@value":"9000344128674"},{"@type":"NRID","@value":"9000400187744"},{"@type":"NRID","@value":"9000410277592"},{"@type":"NRID","@value":"9000413364559"},{"@type":"NRID","@value":"9000414348555"},{"@type":"NRID","@value":"9000266440245"},{"@type":"NRID","@value":"9000321630106"},{"@type":"NRID","@value":"9000411770401"},{"@type":"NRID","@value":"9000409315915"},{"@type":"NRID","@value":"9000409800143"},{"@type":"NRID","@value":"9000314787455"},{"@type":"NRID","@value":"9000345444145"},{"@type":"NRID","@value":"9000398291491"},{"@type":"NRID","@value":"9000322675117"},{"@type":"NRID","@value":"9000389446498"},{"@type":"NRID","@value":"9000314805531"},{"@type":"NRID","@value":"9000404628395"},{"@type":"NRID","@value":"9000398383848"},{"@type":"NRID","@value":"9000018779266"},{"@type":"NRID","@value":"9000411105683"},{"@type":"NRID","@value":"9000367425933"},{"@type":"NRID","@value":"9000375902002"},{"@type":"NRID","@value":"9000415072606"},{"@type":"NRID","@value":"9000340946096"},{"@type":"NRID","@value":"9000325816166"},{"@type":"NRID","@value":"9000356618835"},{"@type":"NRID","@value":"9000020074842"},{"@type":"NRID","@value":"9000390428145"},{"@type":"NRID","@value":"9000408593778"},{"@type":"NRID","@value":"9000361687725"},{"@type":"NRID","@value":"9000410916916"},{"@type":"NRID","@value":"9000404151190"},{"@type":"NRID","@value":"9000241650879"},{"@type":"NRID","@value":"9000398383852"},{"@type":"NRID","@value":"9000380963012"},{"@type":"NRID","@value":"9000241834610"},{"@type":"NRID","@value":"9000415414779"},{"@type":"NRID","@value":"9000273039273"},{"@type":"NRID","@value":"9000387919415"},{"@type":"NRID","@value":"9000319049313"},{"@type":"NRID","@value":"9000414374278"},{"@type":"NRID","@value":"9000410317878"},{"@type":"NRID","@value":"9000242697537"},{"@type":"NRID","@value":"9000398291476"},{"@type":"NRID","@value":"9000402121444"},{"@type":"NRID","@value":"9000399800176"},{"@type":"NRID","@value":"9000283501709"},{"@type":"NRID","@value":"9000375850857"},{"@type":"NRID","@value":"9000411477889"},{"@type":"NRID","@value":"9000399329376"},{"@type":"NRID","@value":"9000241797843"},{"@type":"NRID","@value":"9000411221301"},{"@type":"NRID","@value":"9000266440239"},{"@type":"NRID","@value":"9000259833464"},{"@type":"NRID","@value":"9000257804083"},{"@type":"NRID","@value":"9000414088931"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/dai_yabe"}],"foaf:name":[{"@value":"Daisuke Yabe"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232266634762","@type":"Researcher","foaf:name":[{"@value":"Anu Ambos"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232266634752","@type":"Researcher","foaf:name":[{"@value":"Bertrand Cariou"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232266634760","@type":"Researcher","foaf:name":[{"@value":"Lea Duvnjak"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232266634753","@type":"Researcher","foaf:name":[{"@value":"Marc Evans"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232266634756","@type":"Researcher","foaf:name":[{"@value":"Guillermo González-Gálvez"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232266634761","@type":"Researcher","foaf:name":[{"@value":"Jay Lin"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232266634754","@type":"Researcher","foaf:name":[{"@value":"Elena V. Nikonova"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232266634755","@type":"Researcher","foaf:name":[{"@value":"Pedro de Pablos-Velasco"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232266634758","@type":"Researcher","foaf:name":[{"@value":"Jean-François Yale"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232266634757","@type":"Researcher","foaf:name":[{"@value":"Bo Ahrén"}]}],"contributor":[{"@id":"https://cir.nii.ac.jp/crid/1890020693296665099","@type":"Researcher","foaf:name":[{"@value":"6602972745"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665095","@type":"Researcher","foaf:name":[{"@value":"6504120344"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665103","@type":"Researcher","foaf:name":[{"@value":"6602130037"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665106","@type":"Researcher","foaf:name":[{"@value":"35598746200"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665093","@type":"Researcher","foaf:name":[{"@value":"6508009486"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665107","@type":"Researcher","foaf:name":[{"@value":"23976188300"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665088","@type":"Researcher","foaf:name":[{"@value":"57203632144"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665120","@type":"Researcher","foaf:name":[{"@value":"57189518568"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665094","@type":"Researcher","foaf:name":[{"@value":"6603805479"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665104","@type":"Researcher","foaf:name":[{"@value":"7005769212"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296664962","@type":"Researcher","foaf:name":[{"@value":"326013"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665091","@type":"Researcher","foaf:name":[{"@value":"35462351600"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665121","@type":"Researcher","foaf:name":[{"@value":"6079776"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296664964","@type":"Researcher","foaf:name":[{"@value":"87599"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665112","@type":"Researcher","foaf:name":[{"@value":"444257"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296664832","@type":"Researcher","foaf:name":[{"@value":"642446"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665113","@type":"Researcher","foaf:name":[{"@value":"1305879"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665089","@type":"Researcher","foaf:name":[{"@value":"4346353"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296664833","@type":"Researcher","foaf:name":[{"@value":"739699"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665098","@type":"Researcher","foaf:name":[{"@value":"1908"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665100","@type":"Researcher","foaf:name":[{"@value":"WOS:Yabe, D"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665123","@type":"Researcher","foaf:name":[{"@value":"2062661"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665096","@type":"Researcher","foaf:name":[{"@value":"175901"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665108","@type":"Researcher","foaf:name":[{"@value":"WOS:Ambos, A"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665122","@type":"Researcher","foaf:name":[{"@value":"WOS:Cariou, B"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665115","@type":"Researcher","foaf:name":[{"@value":"WOS:Evans, M"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665102","@type":"Researcher","foaf:name":[{"@value":"WOS:Duvnjak, L"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296664963","@type":"Researcher","foaf:name":[{"@value":"WOS:Gonzalez-Galvez, G"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665109","@type":"Researcher","foaf:name":[{"@value":"WOS:Lin, J"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665105","@type":"Researcher","foaf:name":[{"@value":"WOS:Nikonova, EV"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665101","@type":"Researcher","foaf:name":[{"@value":"WOS:Yale, JF"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296665110","@type":"Researcher","foaf:name":[{"@value":"WOS:Ahren, B"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020693296664961","@type":"Researcher","foaf:name":[{"@value":"WOS:de Pablos-Velasco, P"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"10568727"}],"prism:publicationName":[{"@value":"Journal of Diabetes and its Complications"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2016-09","prism:volume":"30","prism:number":"7","prism:startingPage":"1385","prism:endingPage":"1392"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","http://creativecommons.org/licenses/by-nc-nd/4.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S1056872716301714?httpAccept=text/plain"},{"@id":"https://api.elsevier.com/content/article/PII:S1056872716301714?httpAccept=text/xml"}],"createdAt":"2016-05-25","modifiedAt":"2019-11-03","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Glycated%20Hemoglobin","dc:title":"Glycated Hemoglobin"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=320502%20Endocrinolog%C3%ADa","dc:title":"320502 Endocrinología"},{"@id":"https://cir.nii.ac.jp/all?q=Endocrinology,%20Diabetes%20and%20Metabolism","dc:title":"Endocrinology, Diabetes and Metabolism"},{"@id":"https://cir.nii.ac.jp/all?q=Type%202%20diabetes","dc:title":"Type 2 diabetes"},{"@id":"https://cir.nii.ac.jp/all?q=Middle%20Aged","dc:title":"Middle Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Antidiabetic%20drug","dc:title":"Antidiabetic drug"},{"@id":"https://cir.nii.ac.jp/all?q=Beta%20cell","dc:title":"Beta cell"},{"@id":"https://cir.nii.ac.jp/all?q=GLP-1%20analog","dc:title":"GLP-1 analog"},{"@id":"https://cir.nii.ac.jp/all?q=Endocrinology","dc:title":"Endocrinology"},{"@id":"https://cir.nii.ac.jp/all?q=Glycemic%20control","dc:title":"Glycemic control"},{"@id":"https://cir.nii.ac.jp/all?q=Diabetes%20Mellitus,%20Type%202","dc:title":"Diabetes Mellitus, Type 2"},{"@id":"https://cir.nii.ac.jp/all?q=Insulin-Secreting%20Cells","dc:title":"Insulin-Secreting Cells"},{"@id":"https://cir.nii.ac.jp/all?q=Internal%20Medicine","dc:title":"Internal Medicine"},{"@id":"https://cir.nii.ac.jp/all?q=Antidiabetic%20drug%20;%20Beta%20cell%20;%20GLP-1%20analog%20;%20Glycemic%20control%20;%20Type%202%20diabetes","dc:title":"Antidiabetic drug ; Beta cell ; GLP-1 analog ; Glycemic control ; Type 2 diabetes"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Hypoglycemic%20Agents","dc:title":"Hypoglycemic Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Peptides","dc:title":"Peptides"},{"@id":"https://cir.nii.ac.jp/all?q=32%20Ciencias%20m%C3%A9dicas","dc:title":"32 Ciencias médicas"},{"@id":"https://cir.nii.ac.jp/all?q=Aged","dc:title":"Aged"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040000782192028544","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"24229007"},{"@type":"JGN","@value":"JP24229007"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-24229007/"}],"notation":[{"@language":"ja","@value":"メタボロミクスによる膵β細胞機能制御機構の解明とその臨床応用"},{"@language":"en","@value":"Elucidation of pancreatic beta-cell function by metabolomics and its clinical application"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360011144087579904","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011144143190784","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011144893279360","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145548961024","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021389820375552","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Distinct hypoglycemic effect of different formulations of a fixed ratio of basal insulin plus glucagon-like peptide-1 receptor agonist in a patient with pancreatic diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292618990902016","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Evidence of Reduced β-Cell Function in Asian Indians With Mild Dysglycemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619830623488","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Glucose Sensing in L Cells: A Primary Cell Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620015039488","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Lixisenatide resensitizes the insulin‐secretory response to intravenous glucose challenge in people with type 2 diabetes – a study in both people with type 2 diabetes and healthy subjects"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565169713583232","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360568466133187200","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"C-Peptide Area Under the Curve at Glucagon Stimulation Test Predicts Glucose Improvements by GLP-1 Receptor Analogue: A Retrospective Observational Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094147543424","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Quantification of Insulin Secretion in Relation to Insulin Sensitivity in Nondiabetic Postmenopausal Women"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574096202074368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360588380608347136","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Quality of Life in Japanese People with Type 2 Diabetes Switching from Multiple Daily Insulin Injections to Once-Daily iGlarLixi: SIMPLIFY Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660692883456","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855568803891712","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569751611008","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570793517440","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045024641408","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045399227136","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Little enhancement of meal‐induced glucagon‐like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418518602117632","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993937830400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (\n                    <scp>GetGoal</scp>\n                    ‐P)"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419231021312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Randomized, double‐blind, placebo‐controlled trial of the once‐daily\n                    <scp>GLP</scp>\n                    ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (\n                    <scp>GetGoal</scp>\n                    ‐L‐Asia)"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895297311616","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"SUIT, secretory units of islets in transplantation: An index for therapeutic management of islet transplanted patients and its application to type 2 diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368256279040","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369969640832","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Postprandial serum C‐peptide value is the optimal index to identify patients with non‐obese type 2 diabetes who require multiple daily insulin injection: Analysis of C‐peptide values before and after short‐term intensive insulin therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107371036948992","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843377777536","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Lixisenatide for the treatment of type 2 diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844804221440","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845933454976","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Use and Abuse of HOMA Modeling"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388846049019008","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319697510528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"GIP and GLP‐1, the two incretin hormones: Similarities and differences"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320951504896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793283705472","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794693575424","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Add-on therapies to metformin for type 2 diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795282895872","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Functional Assessment of Pancreatic β-Cell Area in Humans"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795896625664","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Physiology of Glucagon-like Peptide 1"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951796274623232","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269134816896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Enhanced Protection against Cytokine- and Fatty Acid-induced Apoptosis in Pancreatic Beta Cells by Combined Treatment with Glucagon-like Peptide-1 Receptor Agonists and Insulin Analogues"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269749521024","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269768911872","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233271166666368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function"}]},{"@id":"https://cir.nii.ac.jp/crid/1371695769143258244","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)"}]},{"@id":"https://cir.nii.ac.jp/crid/1371695769143258387","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Incretin-based therapies in the management of type 2 diabetes: Rationale and reality in a managed care setting"}]},{"@id":"https://cir.nii.ac.jp/crid/1371695769143258503","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The GLP-1 receptor agonist AVE0010 improves GSIS, prevent lipotoxicity-induced insulin depletion and preserves beta-cell function in human pancreatic islets (abstract)"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.jdiacomp.2016.05.018"},{"@type":"KAKEN","@value":"PRODUCT-20768767"},{"@type":"OPENAIRE","@value":"doi_dedup___::dd1b156f7ed7e3184425a4c5147002f4"},{"@type":"CROSSREF","@value":"10.1007/s13340-023-00621-5_references_DOI_YmHTZWQ1kYuKIIiPKSWm69UGpu5"},{"@type":"CROSSREF","@value":"10.1007/s13300-019-0586-6_references_DOI_YmHTZWQ1kYuKIIiPKSWm69UGpu5"},{"@type":"CROSSREF","@value":"10.1007/s13300-024-01645-z_references_DOI_YmHTZWQ1kYuKIIiPKSWm69UGpu5"}]}